ReviewVirchows Archiv : an international journal of pathology2019
Invited review-next-generation sequencing: a modern tool in cytopathology.
Review in Virchows Archiv : an international journal of pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- A potential inflammatory biomarker for advanced endometrial cancer treated with lenvatinib plus pembrolizumab.The journal of obstetrics and gynaecology research · 2025Article
- The basics of commonly used molecular techniques for diagnosis, and application of molecular testing in cytology.Diagnostic cytopathology · 2023Review
- The application of high-throughput proteomics in cytopathology.Journal of pathology and translational medicine · 2022Review
- Optimization of pre-analytical and analytical steps for DNA and RNA analysis of fresh cytology samples.Cancer medicine · 2022Article
- Practice guidelines forJournal of medical genetics · 2022Review
- Evaluating Pancreatic and Biliary Neoplasms with Small Biopsy-Based Next Generation Sequencing (NGS): Doing More with Less.Cancers · 2022Review
- The rapidly evolving landscape of biomarker testing in non-small cell lung cancer.Cancer cytopathology · 2021Article
- Molecular Testing on Cytology for Gene Fusion Detection.Frontiers in medicine · 2021Review
- Molecular Profiling of Malignant Pleural Effusions with Next Generation Sequencing (NGS): Evidence that Supports Its Role in Cancer Management.Journal of personalized medicine · 2020Review
- Analytical validation of a novel targeted next-generation sequencing assay for mutation detection in thyroid nodule aspirates and tissue.Endocrine · 2020Article
- Next-generation sequencing analysis of endometrial screening liquid-based cytology specimens: a comparative study to tissue specimens.BMC medical genomics · 2020Article
- Acquiring tissue for advanced lung cancer diagnosis and comprehensive biomarker testing: A National Lung Cancer Roundtable best-practice guide.CA: a cancer journal for cliniciansArticle
- Minimally Invasive Cytopathology and Accurate Diagnosis: Technical Procedures and Ancillary Techniques.In vivo (Athens, Greece)Review
- Molecular testing of cytology specimens: overview of assay selection with focus on lung, salivary gland, and thyroid testing.Journal of the American Society of CytopathologyReview
- Treatment of extended RAS/PharmacogenomicsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, cytopathology has established itself as an independent diagnostic modality to guide clinical management in many different settings. The application of molecular techniques to cytological samples to identify prognostic and predictive biomarkers has played a crucial role in achieving this goal. While earlier studies have demonstrated that single biomarker testing is feasible on cytological samples, currently, this provides only limited and increasingly insufficient information in an era where an increasing number of biomarkers are required to guide patient care. More recently, multigene mutational assays, such as next-generation sequencing (NGS), have gained popularity because of their ability to provide genomic information on multiple genes. The cytopathologist plays a key role in ensuring success of NGS in cytological samples by influencing the pre-analytical steps, optimizing preparation types and adequacy requirement in terms of cellularity and tumor fraction, and ensuring optimal nucleic acid extraction for DNA input requirements. General principles of the role and potential of NGS in molecular cytopathology in the universal healthcare (UHC) European environment and examples of principal clinical applications were discussed in the workshop that took place at the 30th European Congress of Pathology in Bilbao, European Society of Pathology, whose content is here comprehensively described.
Indexed as
Identifiers
30877381What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.